biostudies-literatureUnknown16Zhou L<h4>Background</h4>Transmural healing (TH) is a potential therapeutic goal of Crohn's disease (CD) and is associated with better clinical outcomes. However, few studies have described early TH and its predictors.<h4>Objectives</h4>We aimed to evaluate early TH and its predictors using magnetic resonance enterography (MRE) in patients with CD receiving ustekinumab (UST).<h4>Design</h4>This was a retrospective observational study.<h4>Methods</h4>Patients with active CD treated with UST and their intestinal segments with bowel wall thickness (BWT) ⩽ 3 mm at baseline were included. Clinical characteristics, laboratory indicators, endoscopic manifestations, and MRE indices were evaluated at baseline and week 26 (W26) of the therapy. The following MRE parameters were assessed: BWT, edema, appareTherapeutic advances in gastroenterology17562848231170947https://www.ebi.ac.uk/biostudies/studies/S-EPMC10164861biostudies-literatureEarly transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn's disease receiving ustekinumab.PMC10164861Qiu YZhou LLi XHu CLiu ZHe YChen MMao RZeng ZWang YZhang RChen BfalseEarly transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn's disease receiving ustekinumab.<h4>Background</h4>Transmural healing (TH) is a potential therapeutic goal of Crohn's disease (CD) and is associated with better clinical outcomes. However, few studies have described early TH and its predictors.<h4>Objectives</h4>We aimed to evaluate early TH and its predictors using magnetic resonance enterography (MRE) in patients with CD receiving ustekinumab (UST).<h4>Design</h4>This was a retrospective observational study.<h4>Methods</h4>Patients with active CD treated with UST and their intestinal segments with bowel wall thickness (BWT) ⩽ 3 mm at baseline were included. Clinical characteristics, laboratory indicators, endoscopic manifestations, and MRE indices were evaluated at baseline and week 26 (W26) of the therapy. The following MRE parameters were assessed: BWT, edema, appare2023-01-01T00:00:00Z20232025-04-26T17:20:35.679Z2025-04-06T15:31:49.711ZS-EPMC101648613716840410.1177/17562848231170947